Harrow, Inc. (HROW)

NGM – Real Time Price. Currency in USD

29.03

-9.01 (-23.69%)

At close: May 12, 2026, 4:00 PM EDT

29.90

+0.87 (3.00%)

Pre-market: May 13, 2026, 7:38 AM EDT

12.05.2026

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript

12.05.2026

Harrow Q1 Earnings Call Highlights

Harrow NASDAQ: HROW executives said the company's first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized that underlying demand for its core ophthalmic products is accelerating.

11.05.2026

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

Harrow (HROW) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.38 per share a year ago.

11.05.2026

Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to deliver 2026 revenue of over $100 million Quarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 million IHEEZO® unit demand increased 18% year-over-year, with 82% of units from retina accounts TRIESENCE® unit demand more than doubled year-over-year, the sixth consecutive quarter of growth Second Quarter revenue expected between $71 million and $81 million Full-year 2026 revenue guidance reaffirmed at $350 million to $365 million Cash and cash equivalents of $94.6 million as of March 31, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

04.05.2026

Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

27.04.2026

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the market close.

20.04.2026

Harrow: Now Is The Buy Time

Harrow has delivered a decade-long 40% CAGR in revenue, with robust operating leverage and EBITDA margin expansion. Seasonal weakness in Q1 consistently creates compelling entry points, with share prices typically bottoming near the Q1 report date and rebounding sharply later in the year. HROW's 2026 low of $33 suggests a likely move to $100 within the year, reflecting the historical pattern of annual highs being about 3x annual lows.

Videos

No Data

There is no data to display

Press releases

11.05.2026

Harrow Announces First Quarter 2026 Financial Results

16.04.2026

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclonidine hydrochloride ophthalmic solution) has been assigned a permanent J-Code (J2374) by the Centers for Medicare & Medicaid Services (CMS).

14.04.2026

LogiCare3PL Selected as Distribution Partner by Harrow

OLIVE BRANCH, Miss., April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions.

24.03.2026

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the “2030 Notes”).

Harrow, Inc. (HROW)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Harrow, Inc. (HROW)